Literature DB >> 20671295

Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.

Joshua A Lile1, Shanna Babalonis, Cleeve Emurian, Catherine A Martin, Daniel P Wermeling, Thomas H Kelly.   

Abstract

Recent reports indicate an increase in intranasal use of prescription oral stimulant medication. However, there do not appear to be any published clinical studies that have characterized the behavioral and cardiovascular effects of intranasally administered d-amphetamine, which is commonly prescribed for Attention Deficit Hyperactivity Disorder. In this study, a range of d-amphetamine doses (0, 16, 24, and 32 mg/70 kg) were administered as an intranasal solution delivered using a mucosal atomization device. Equal oral doses were included for comparison. Assessments were conducted before and at regular intervals for 3 hours following drug administration and included self-reported drug-effect questionnaires, cardiovascular indices, a performance task, and 2 measures of impulsivity. d-Amphetamine produced prototypical stimulant effects (eg, increased subject ratings of Stimulated and Like Drug, elevated heart rate and blood pressure, and improved rate and accuracy on the digit symbol substitution task) irrespective of dose, but the onset of these effects was generally earlier following intranasal administration, with significant effects emerging 15 to 30 minutes after intranasal dosing and 45 to 60 minutes after oral dosing. These results demonstrate that intranasal administration of d-amphetamine results in a more rapid onset compared to oral dosing, which could be associated with the popularity of intranasal prescription stimulant use and an enhanced potential for abuse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671295      PMCID: PMC3684273          DOI: 10.1177/0091270010375956

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  35 in total

1.  Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART).

Authors:  C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown
Journal:  J Exp Psychol Appl       Date:  2002-06

2.  Relationship of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in healthy volunteers.

Authors:  Sheila J Asghar; Veronique A M I Tanay; Glen B Baker; Andy Greenshaw; Peter H Silverstone
Journal:  Hum Psychopharmacol       Date:  2003-06       Impact factor: 1.672

3.  Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose-response analysis.

Authors:  William W Stoops; Paul E A Glaser; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2003-08-20       Impact factor: 4.492

4.  Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects.

Authors:  B Angrist; J Corwin; B Bartlik; T Cooper
Journal:  Biol Psychiatry       Date:  1987-11       Impact factor: 13.382

5.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.

Authors:  W R Martin; J W Sloan; J D Sapira; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

6.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action.

Authors:  G Winger; S R Hursh; K L Casey; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

8.  Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications.

Authors:  Jennifer Setlik; G Randall Bond; Mona Ho
Journal:  Pediatrics       Date:  2009-08-24       Impact factor: 7.124

9.  Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder.

Authors:  Martha Coetzee; Yifrah Kaminer; Arthuro Morales
Journal:  Subst Abus       Date:  2002-09       Impact factor: 3.716

10.  Effects of dose and infusion delay on cocaine self-administration choice in rhesus monkeys.

Authors:  Karen G Anderson; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2003-04-11       Impact factor: 4.530

View more
  11 in total

1.  Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance.

Authors:  Alison Looby; Mitch Earleywine
Journal:  Exp Clin Psychopharmacol       Date:  2011-08-29       Impact factor: 3.157

2.  Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans.

Authors:  Matthew G Kirkpatrick; Erik W Gunderson; Chris-Ellyn Johanson; Frances R Levin; Richard W Foltin; Carl L Hart
Journal:  Addiction       Date:  2012-04       Impact factor: 6.526

3.  Recent Translational Findings on Impulsivity in Relation to Drug Abuse.

Authors:  Jessica Weafer; Suzanne H Mitchell; Harriet de Wit
Journal:  Curr Addict Rep       Date:  2014-12-01

Review 4.  Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.

Authors:  Marisa E Marraccini; Lisa L Weyandt; Joseph S Rossi; Bergljot Gyda Gudmundsdottir
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

Authors:  David H Winslow; Charles H Bowden; Karen P DiDonato; Pamela A McCullough
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

6.  Separate and Combined Effects of Naltrexone and Extended-Release Alprazolam on the Reinforcing, Subject-Rated, and Cardiovascular Effects of Methamphetamine.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  J Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.153

7.  Prescription Stimulant Misuse and Diversion Events Among College Students: A Qualitative Study.

Authors:  Candelaria Garcia; Brian Valencia; Kate Diaz Roldan; Jacquelyn Garcia; Jeovanna Amador Ayala; Alison Looby; Jaimie McMullen; Niloofar Bavarian
Journal:  J Prev (2022)       Date:  2021-11-02

8.  Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls.

Authors:  Anouk Schrantee; Bart Ferguson; Diederick Stoffers; Jan Booij; Serge Rombouts; Liesbeth Reneman
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

9.  Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects.

Authors:  Patrick C Dolder; Petra Strajhar; Patrick Vizeli; Felix Hammann; Alex Odermatt; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2017-09-07       Impact factor: 5.810

10.  Rejecting impulsivity as a psychological construct: A theoretical, empirical, and sociocultural argument.

Authors:  Justin C Strickland; Matthew W Johnson
Journal:  Psychol Rev       Date:  2020-09-24       Impact factor: 8.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.